Stay updated with breaking news from Amend Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On October 4, 2022, the United States Patent and Trademark Office (USPTO) announced that it would be extending the Motion to Amend (MTA) Pilot Program at the Patent Trial and Appeal Board (PTAB)...
On October 4, 2022, the United States Patent and Trademark Office (USPTO) announced that it would be extending the Motion to Amend (MTA) Pilot Program at the Patent Trial and Appeal...
No Unpatentability in a Successful Motion to Amend Tuesday, February 23, 2021 Mylan Labs. Ltd. v. Aventis Pharma S.A., IPR2016-00712, Paper 112 (P.T.A.B. Oct. 22, 2019), aff’d without opinion (Fed. Cir. Jan. 15, 2021), the Patent Trial and Appeal Board (“PTAB”) granted Patent Owner’s motion to amend, finding that Petitioner had not shown the proposed substitute claims to be unpatentable. Background The drug at issue was JEVTANA ® (cabazitaxel), which is indicated for use in combination with prednisone for the treatment of patients with metastatic castration-resistant pr...